30results about "X-ray constrast preparations" patented technology

The present application relates to the technical field of disease detection, and more particularly to a method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM, which comprises the following steps: S1: assembling CeOx with a MMP2 specific probe to form a CeOx-P compound; and S2: coating the CeOx-P compound with a biomimetic platelet membrane as a carrier to assemble CeOx-P@PM nanoparticles. The method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM has the excellent characteristics of efficient ROS removal, high bioavailability, lesion targeting, and dual-mode precise imaging, and will provide great help for the diagnosis and treatment of early atherosclerotic plaques in clinical practice.

The application discloses a silk fibroin nanocage and application thereof. The silk fibroin nanocage is self-assembled from silk fibroin fragments with a specific molecular weight distribution, and the size of the nanocage can be regulated by selecting different molecular weight fragments. The nanocage is used as a template to guide the reaction of metal ions and a sulfur source in a strong alkali environment, so that metal sulfide nanoparticles with a core-shell structure can be prepared, and the particle size can be controlled in the range of 5-50 nm. By selecting nanocage templates with different molecular weights, the functions of the nanoparticles can be directionally optimized, so that the nanoparticles are respectively applicable to efficient photothermal therapy, high-contrast medical imaging, or photothermal immune synergistic therapy and tissue repair. The application realizes universal and accurate regulation of the size and function of nanomaterials from a template source, and the nanoparticle products have good biocompatibility and excellent performance, and have wide application prospects in the fields of tumor diagnosis and treatment, antibacterial and anti-inflammatory, and regenerative medicine.

The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and / or an increase in activation of TLR-4.

The application belongs to the technical field of barium compound preparation, and relates to a preparation method of nano barium sulfate. The method adopts an in-situ degradable dispersant based on a natural polysaccharide derivative, adsorbs on the surface of a barium sulfate crystal nucleus through a functional group in the reaction to inhibit agglomeration, adjusts the pH to 3.0-6.0 after the reaction is completed, and acid-catalytically hydrolyzes the dispersant into a water-soluble small molecule, so that a high-purity and high-dispersibility product can be obtained through simple water washing. The application introduces a natural polysaccharide derivative with a crystal face selective adsorption capacity and an acid-triggered degradation characteristic as an in-situ degradable dispersant, and constructs a new green preparation paradigm of nano barium sulfate with reaction-dispersion-self-cleaning integration. The method fundamentally eliminates the risk of organic impurity residue without sacrificing the dispersing performance, significantly improves the product purity and application safety, simultaneously simplifies the post-processing technology, reduces the energy consumption and wastewater treatment cost, and has both technical advancement and industrialization feasibility.

The present application relates to a kind of iodine-containing compounds with X-ray imaging function and its application, belong to the field of tissue imaging.The present application provides a kind of iodine-containing compounds with X-ray imaging function, this iodine-containing compound is completely different from the existing iodine-containing contrast agent such as iodixanol in structure, and, this iodine-containing compound viscosity is lower than iodixanol, iodine content is higher than iodixanol, as the performance of iodine-containing contrast agent is superior.

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

In some aspects, the present disclosure pertains to systems that comprise (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties, (b) a reactive multifunctional compound comprising a plurality of second reactive moieties, and (c) gold nanoparticles that are functionalized with a plurality of second hydrophilic polymer segments. In other aspects, the present disclosure pertains to crosslinked reaction products formed from such systems. In further aspects, the present disclosure pertains to methods of treatment using systems and such crosslinked reaction products.

The present disclosure is directed to a class of fluorinated copolymers, such as TFE copolymers, that can be dispersed in a liquid carrier including low toxicity liquid solvents, such as Class III Solvents, and that enable the creation of stable dispersions including the fluorinated copolymers dispersed in a liquid carrier including a water miscible organic component and an aqueous component.

Disclosed are a method, device, and system for X-ray CT contrast imaging using magnetic nanoparticles. The method includes: rotating a target object containing magnetic nanoparticles as contrast agent for one circle relative to X-rays, recording multiple consecutive transmission projection images of the target object at all angles; for multiple transmission projection images at each angle, after conducting image post-processing operations, performing inverse projection transform on magnetic nanoparticle imaging projection images at all angles to obtain a tomographic imaging result. The image post-processing operation includes: time-frequency transform: converting the third dimension of the three-dimensional time domain matrix to frequency domain to obtain a three-dimensional frequency domain matrix; feature extraction: selecting a two-dimensional matrix with frequency of kf along the third dimension of the three-dimensional frequency domain image matrix; k is a positive integer; f is the frequency of the excitation magnetic field.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

The application discloses a novel bismuth-based chelate CT contrast agent and a preparation method and application thereof. The synthesis method comprises the following steps: 2,6-pyridine dimethyl alcohol is reacted with chlorosulfoxide to obtain 2,6-bis(chloromethyl)pyridine; the 2,6-bis(chloromethyl)pyridine is reacted with N,N',N''-tris(p-tolylsulfonyl)divinyltriamine and an inorganic base in a solvent and is heated, is deprotected by concentrated sulfuric acid to obtain an intermediate pyclen; the pyclen is heated and reacted with a halogenated carboxylic acid ester under alkaline conditions in a polar organic solvent, is hydrolyzed to obtain a ligand product; and the ligand product is heated and chelated with a bismuth agent to obtain the target bismuth-based chelate. The application realizes the laboratory scale preparation of the small-molecule bismuth-based chelate CT contrast agent, and a non-ionic contrast agent is prepared, which has low osmotic pressure, high stability, high water solubility and good biological safety and is used for CT imaging of the digestive system, the urinary system and the circulatory system.

This invention discloses a targeted nanocarrier for the diagnosis and treatment of arterial dissection and its preparation method. The targeted nanocarrier is composed of a macromolecular prodrug self-assembly constructed by covalently linking the NLRP3 inhibitor CY-09 and oxidized fucoidan through phenylboronic acid ester bonds and imine bonds, using iodine contrast agent ICA as a connecting bridge. The targeted nanocarrier prepared by this invention possesses good stability, drug release characteristics, excellent dissection targeting, and dual responsiveness to reactive oxygen species and acidic microenvironments, demonstrating significant imaging diagnostic and therapeutic effects on arterial dissection.

The present invention provides a composition. The composition includes a micelle having an outer shell containing one or more polymer-flavonoid conjugates, an inner shell optionally containing one or more flavonoid oligomers, and an imaging agent encapsulated within the shell. The present invention also provides a method for performing an imaging diagnosis using the composition.

This invention belongs to the field of biomedical materials technology, and relates to a signal probe that simultaneously possesses CT and MRI imaging capabilities, its preparation method, and its application. The preparation method includes the following steps: dissolving bismuth citrate and iron salt in water, adjusting the pH of the solution to <7, adding polyvinylpyrrolidone, then adding gallic acid, adjusting the pH of the mixed solution to >7, and after the reaction is complete, filtering through a membrane to remove impurities, dialysis, and drying to obtain bismuth-iron nanoparticles; mixing citric acid with the bismuth-iron nanoparticle solution, stirring and reacting to obtain citric acid-treated bismuth-iron nanoparticles; further activating to obtain an activated bismuth-iron nanoparticle solution; adding RGDfk and amino-terminated polyethylene glycol to the activated bismuth-iron nanoparticle solution, stirring and reacting in the dark, dialysis, and drying to obtain a signal probe that simultaneously possesses CT and MRI imaging capabilities. The signal probe prepared by this invention has a small particle size and simultaneously possesses CT and MRI imaging functions.

The present disclosure is directed to a class of fluorinated copolymers, such as TFE copolymers, that can be dispersed in a liquid carrier including low toxicity liquid solvents, such as Class III Solvents, and that enable the creation of stable dispersions including the fluorinated copolymers dispersed in a liquid carrier including a water miscible organic component and an aqueous component.

The present invention relates to a lipiodol-based composite embolic agent of active metal microspheres or nano-hydrides, a preparation method therefor, and applications thereof. It belongs to the technical field of medicines. The composite embolic agent of the present invention is composed of lipiodol and active metal microspheres or nano-hydrides, wherein the lipiodol serves as a dispersant and a protectant that can decrease the reaction rate of the active metal microspheres or nano-hydrides with water. Methods for preparing the active metal microspheres and the nano-hydrides involved in the present invention are simple, and can be used for mass preparation in a short time. The composite embolic agent prepared in the present invention is locally delivered to liver tumor tissues by interventional operation to allow deposition of lipiodol on the liver tumor tissue to induce embolization; in addition, active metal microspheres or hydrides release hydrogen in situ to induce hydrogen treatment, thereby amplifying the embolization effect. The composite embolic agent as defined in the present invention regulates tumor microenvironment by in situ release of hydrogen, hydroxide, or the like from the active metal microspheres or hydrides, showing a better combined embolization effect than simple lipiodol embolization.

Contrast agents for x-ray imaging including stabilized metal nanoparticles and encapsulated nanoparticles, as well as methods for imaging tissue with these agents, are disclosed. Also disclosed are methods of dual energy x-ray imaging using metal nanoparticle contrast agents or encapsulated metal nanoparticles.

This invention relates to the field of organic synthesis technology, specifically to an iodinated fatty acid ester, its preparation method, and its applications. The preparation method involves carrying out an iodination reaction of an unsaturated fatty acid ester in a mixed system of triphenylphosphine and elemental iodine. The preparation method of this invention is efficient, controllable, highly selective, and capable of generating stable iodinated fatty acid esters, thus expanding the application fields of iodinated polyunsaturated fatty acids.

This invention relates to a method for preparing iodine-based nanocontrast agents. Based on the specific and efficient esterification reaction between fluorinated phenylboronic acid groups and ortho-dihydroxy structures, an amphiphilic block polymer containing fluorinated phenylboronic acid groups is co-crosslinked with water-soluble nonionic polyhydroxy iodine-based contrast agents such as iohexol, iodofol, iodixanol, iopromide, iodomeprazole, iodiphenol, iodpentol, and iotram. No chemical modification of the iodine-based contrast agents is required. The water-soluble nonionic polyhydroxy iodine-based contrast agents can be easily and efficiently nano-sized through the phenylboronic acid esterification crosslinking reaction to obtain iodine-based nanocontrast agents. This invention has the advantages of a simple and controllable preparation process, mild reaction conditions, inexpensive and readily available raw materials, and no toxic byproducts. Furthermore, the prepared iodine-based nanocontrast agents exhibit good dispersion stability and excellent imaging contrast performance. When the concentration of the iodine-based nanocontrast agent reaches 120 mg / mL, the CT value reaches as high as 1150 HU.

This application relates to the field of medical preparation technology, specifically to a multi-visualizable magnetic fluid, its preparation method, and a magnetic fluid occluder. The multi-visualizable magnetic fluid is suitable for obstructing blood flow within blood vessels. The magnetic fluid comprises: ethylene-vinyl alcohol copolymer (EVOH), dimethyl sulfoxide (DMSO), sodium polyacrylate (PAANa), iron oxide nanoparticles, iopromide, polyvinyl alcohol (PVA), and perfluoropentane. This magnetic fluid can reduce the risk of misembolization in distal normal tissues or important branch vessels, improving the safety of vascular interventional therapy. Furthermore, under the control of an external magnetic field, it can actively avoid dangerous vascular branches, achieving reverse blood flow into the target area, effectively improving the precision of treatment. Moreover, it possesses multi-visualization properties, enabling real-time positioning of the injected magnetic fluid in the lesion area via ultrasound imaging, facilitating the meeting of diverse intraoperative imaging monitoring needs.

The present application relates to the technical field of contrast agents, in particular to a gadolinium complex, a preparation method and application thereof. The gadolinium complex provided by the present application takes PAMAM as a ligand, PAMAM has good biocompatibility and controllable in-vivo metabolic behavior, can prolong the circulation time of the contrast agent and reduce the systemic toxicity; in addition, PAMAM has a regular spherical structure and an internal cavity, and can realize efficient loading of Gd ions; the gadolinium complex provided by the present application integrates multiple gadolinium ions in one molecule, forms a local and high-density 'gadolinium atom group', has high contrast efficiency, and can provide a stronger X-ray attenuation signal than a conventional gadolinium complex (such as gadoterate) under the same dosage (mass or molar concentration), thereby realizing high-definition imaging under a lower dosage or obtaining a stronger contrast under a conventional dosage, which is particularly valuable for the display of fine structures such as blood vessels and tumors.

This invention belongs to the field of biomedicine and pharmaceutical technology, and discloses a liposome delivery system for thymus-targeted imaging and / or treatment, its preparation method, and applications. The delivery system uses liposomes as carriers and modifies the carriers with terminal carboxyl-modified polyethylene glycol-phospholipid derivatives (DSPE-PEG-COOH) to form functionalized liposome structures. It can efficiently encapsulate iodine contrast agents (e.g., iodixanol) and covalently couple CD205 antibodies to the liposome surface, thereby achieving active targeting of thymic epithelial cells. This system can enhance the specificity and stability of thymus CT imaging. Furthermore, this delivery platform can also be used to load various therapeutic drugs (such as hydroxyflutamide), achieving local drug accumulation in the thymus region, enhancing the intervention effect while effectively reducing systemic toxicity.

The present invention pertains to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein in formula (1), R1 to R3 each independently are a predetermined amino group, a predetermined amide group, or a group represented by formula (2), and at least one among R1 to R3 is a group represented by formula (2).

In some aspects, the present disclosure provides reactive polymers that comprise one or more hydrophilic polymer segments having a plurality of hydrophilic polymer segment ends and a plurality of reactive moieties covalently linked to at least a portion of the hydrophilic polymer segment ends. The reactive moieties are 3,4-substituted-2,5-pyrrolidinedione moieties in which the 3-carbon and the 4-carbon form part of at least one ring in addition to the 2,5-pyrrolidinedione ring, and the 2,5-pyrrolidinedione ring nitrogen atom of each of the 3,4-substituted-2,5-pyrrolidinedione moieties is linked to one of the hydrophilic polymer segment ends. In other aspects, the present disclosure provides systems for forming hydrogel compositions and methods of treatment that employ such reactive polymers and methods of synthesizing such reactive polymers.

In some aspects, the present disclosure provides a hydrogel comprising (a) a reactive multi-armed polymer comprising a plurality of reactive moieties and (b) a crosslinking reaction product of a multifunctional crosslinking compound having a plurality of complementary reactive moieties that react with the reactive moieties of the reactive multi-armed polymer, the hydrogel comprising hydrolysable moieties as described herein dispersed throughout the hydrogel. Other aspects of the present disclosure relate to reactive multi-armed polymers and multifunctional crosslinking compounds for use in forming such hydrogels, as well as crosslinkable systems for forming such hydrolysable hydrogels.

This document discloses a polymer for application at a treatment site to form a hydrogel, thereby physically separating / isolating target tissue for radiotherapy. The polymer comprises: a first monomer for binding water; a second monomer for imparting mechanical properties; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase transition behavior. Preferably, the first monomer is OEGMA; the second monomer is PLA / HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm. The polymer comprises: about 1 to about 15 mol% of OEGMA; 5 mol% to about 50 mol% of PLA / HEMA; 0 mol% to about 15 mol% of NAS; and up to about 85 mol% of NIPAAm. Preferably, the target tissue is a human prostate. Preferably, the polymer is applied in an aqueous solution, such as saline, at a concentration up to about 280 mg / mL.

The present invention relates to a method for preparing a filling material for cerebral aneurysm embolization, and use thereof. The filling material for cerebral aneurysm embolization, prepared according to the preparation method of the present invention, and thus can contribute to increasing the success rate of embolization and improving the safety of surgery, thereby being suitable for use in actual cerebral aneurysm embolization procedures.

An implantable device for delivering a polymeric drug compound is provided. The device includes a core having an outer surface and a membrane layer disposed adjacent to the outer surface of the core. The core includes a core polymer matrix having a drug compound dispersed therein, the polymer matrix containing a hydrophobic polymer. The membrane layer further includes a membrane polymer matrix having the polymeric drug compound optionally dispersed therein. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of hydrophobic polymer to hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200. [Selected Figure] Figure 1

The present disclosure provides a customizable lyophilized agent and its use for cancer treatment. The agent comprises a biocompatible lyophilized matrix and nanoparticles incorporated within the lyophilized matrix. The lyophilized matrix is reconstitutable with a biocompatible solvent to form a colloid. The nanoparticles provide imaging contrast for at least one imaging modality. The nanoparticles may provide contrast for both computed tomography and magnetic resonance imaging. The lyophilized matrix may be reconstituted with an aqueous solution of a therapeutic agent, allowing for customization of the agent for specific treatment needs.

This invention discloses a nano-heterojunction radiosensitizer suitable for hypoxic tumors and its preparation method. The radiosensitizer is a core-shell structured nanoparticle, comprising a core and a shell. The core is a high-valence bismuth-based nanomaterial, including at least one of sodium bismuthate, silver bismuthate, and potassium bismuthate. The shell coats the surface of the core and comprises a metal oxide. A Z-shaped heterojunction is formed between the inner core and the outer shell. Under X-ray excitation, this heterojunction forms a built-in electric field, promoting electron-hole separation. Electrons in the high-valence bismuth nanoparticle phase reduce high-valence bismuth (Bi). 5+ →Bi 3+ ) and releases highly reactive lattice oxygen, which then reacts with holes on the TiO2 phase to generate singlet oxygen ( 1 O2), while the holes on TiO2 oxidize water molecules to produce hydroxyl radicals (•OH).